hypothesis, as chronic exposure to caffeine in the drinking water of rats resulted in 26 tolerance to the performance benefit of a subsequent acute caffeine dose (Karcz-27 Kubicha et al., 2003) . Although these findings have been confirmed in other animal 28 models (Quarta et al., 2004) , the doses administered have been large (i.e. 130 29 mg·kg·day −1 ) and much greater than those typically consumed by the general 30 population (Fitt et al., 2013) . Whether the same tolerance develops after habituation 31 to doses typically consumed by the general population is not clear. 32
The magnitude of performance benefit after an acute 5 mg·kg −1 caffeine dose was 33 less pronounced in individuals already habituated to caffeine (>300 mg·day −1 ) than 34 their caffeine-naive counterparts (Bell & McLellan, 2002) . Similar metabolic 35 responses have occurred after an acute caffeine dose in comparisons of low-and 36 high-habitual caffeine users (Bangsbo, Jacobsen, Nordberg, Christensen, & Graham, 37 1992 ). However, sub-chronic intake (5 days) both of low (3 mg·kg (Irwin et al., 2011) . These data suggest that a greater duration of supplementation is 43 required before the performance benefit of an acute caffeine dose becomes 44 compromised. To date, no study has systematically evaluated a prolonged period of 45 controlled caffeine intake and its influence on endurance performance. Hence, the 46 aim of this study was to examine the effect of a four-week period of controlledcaffeine supplementation on endurance performance. ; W max : 289 ± 46 W) were 53 recruited and completed this study. All participants were free from chronic disease 54 and deemed eligible to participate after the completion of a health screen 55 questionnaire. Habitual caffeine intake was assessed using a modified version of a 56 semi-quantitative food-frequency questionnaire (Addicot, Yang, Peiffer, & Laurienti, 57 2008) to ensure intake did not exceed 75 mg·day −1 . This cut-off point was chosen as 58 it equates to approximately one cup of caffeinated instant coffee (Fitt et al., 2013) 59 and is similar to what has been used previously (Bell & McLellan, 2002) . The study 60 was approved by the Ethics Approvals (Human Participants) Sub-Committee at 61
Loughborough University, UK. 62
63

Experimental Design 64
The experimental design is illustrated in Fig 1. All participants attended the 65 laboratory on six occasions. During the initial visit each participant undertook an 66 incremental exercise test to volitional exhaustion on an electronically braked cycle 67 ergometer (Lode Corival, Groningen, the Netherlands) to determine V O 2peak and 68 peak power output at V O 2peak (W max ) After this visit, each participant completed one 69 practice trial. This was undertaken to ensure that all participants were accustomed to 70 procedures, to minimise order effects from learning or anxiety and ensure attainment 71 of a maximal effort during the performance task.7 trial. No strenuous exercise, alcohol, or caffeine ingestion was permitted during the 98 24 hr before any laboratory visit. However, the caffeine provided in the capsules was 99 permitted during the 24 hr before the postcaf trial (caffeine group). No additional 100 dietary caffeine was permitted during the supplementation period in both groups and 101 participants were provided with a list of commonly consumed caffeinated foods and 102 beverage to help achieve this. Participants were also instructed to maintain their 103 usual dietary and exercise patterns throughout the supplementation period. 104
Compliance to these measures was verified at the start of each visit, before any data 105 collection. Finally, all trials were performed at the same time of day to minimise 106 circadian-type variations in performance. 107
108
Experimental trials 109
Participants arrived at the laboratory after an overnight fast (8-10 hr) with the 110 exception of ingesting 500 mL of plain water approximately 90 min before. Upon 111 arrival, post-void nude body mass was recorded to the nearest 10 g (Adam AFW-112 120K, Milton Keynes, UK) and a heart rate telemetry band (Polar Beat, Kempele, 113 Finland) positioned. After 10 min of supine rest, a 21g cannula was inserted into an 114 antecubital vein to allow repeated blood sampling. The cannula was flushed with a 115 small volume of saline after each sample to ensure patency. A baseline blood 116 sample (7 mL) was collected before participants ingested either 3 mg·kg −1 of 117 anhydrous caffeine (precaf and postcaf) or 250 mg of starch (testpla). After 60 min 118 rest, a second 7 mL venous blood sample was drawn before participants cycled for 119 60 min at an intensity equivalent to 60% V O 2peak . During this period heart rate and 120 rating of perceived exertion (RPE) were recorded every 5 and 10 min, respectively8 (Borg, 1982) . One-minute expired air samples were collected into Douglas bags 122 every 15 min to determine the rates of fat and carbohydrate oxidation (Peronnet & 123 Massicotte, 1991) . Oxygen and carbon dioxide concentrations in each bag were 124 determined with a paramagnetic analyser (Servomex 1400, Sussex, UK) calibrated 125 against gases of known concentration on the morning of each trial. Total volume was 126 quantified (Harvard Dry Gas Meter, Harvard Apparatus, USA) and gas values were 127 expressed as STPD. After each sample was collected, participants were provided 128 with 100 mL of plain water. A third 7 mL blood sample was collected immediately 129 after the fixed-intensity exercise. 130
After this, there was a 2-3 min delay while the ergometer was set for the 131 performance task. Performance was assessed as the maximum amount of external 132 work (kJ) that could be completed in 30 min. This method is consistent with previous 133 studies (Jenkins, Trilk, Singhal, O'Connor, & Cureton, 2008) and reflected the high 134 ecological validity associated with similar cycle-based performance tests 135 (Jeukendrup, Saris, Brouns, & Kester, 1996) . Participants began exercise at 75% 136 V O 2peak , but were free to adjust the intensity of exercise from the outset. During the 137 performance task participants were instructed to maintain a constant cadence. No 138 verbal encouragement was given during this period and contact was limited to the 139 recording of the physiological and perceptual variables. Heart rate was recorded 140 every 5 min and RPE at 10 and 20 min, respectively. A final 7 mL blood sample was 141 collected at completion of exercise, after which the cannula was removed. 142 143 144 was dispensed into tubes containing K 2 EDTA. Duplicate 100 μL sub-samples were 148 rapidly deproteinised in 1 mL of ice-cold 0.3 M perchloric acid. These were 149 centrifuged and the resulting supernatant was used to determine blood glucose 150 concentrations (GOD-PAP, Randox Ltd, UK). Haemoglobin was measured in 151 duplicate (cyanmethemoglobin method) and haematocrit in triplicate 152 (microcentrifugation). These values were used to estimate percentage changes in 153 blood and plasma volumes relative to the resting sample (Dill & Costill, 1974) . The 154 remaining blood (5 mL) was dispended into tubes containing clotting activator and 155 left at room temperature for at least 60 min before centrifugation at 3000 rpm for 10 156 min at 4°C. The supernatant was stored at -21°C for the determination of serum 157 prolactin and cortisol in duplicate via ELISA (DRG diagnostics, Germany) and serum 158 caffeine in duplicate with reverse-phase HPLC as previously described (Holland, 159 Godfredsen, Page, & Connor, 1998) . The intra-assay coefficient of variation (CV) for 160 serum prolactin, cortisol and caffeine was 4.9%, 5.3% and 2.9%, respectively. 161
162
Statistical analysis 163
All data were analysed using IBM SPSS statistics version 21.0. Normality was 164 assessed with the Shapiro Wilk test. Between-group comparisons of self-reported 165 habitual caffeine intake, stature, body mass, age, V O 2peak and W max were determined 166 with t-tests for independent samples. Repeated measurements of body mass, 167
V O 2peak and W max were analysed using a two-way (group x time) mixed-design 168 factorial ANOVA. Exercise performance and fasting plasma glucose were analysed 169 using a two-way (group x trial) mixed-design factorial ANOVA. Variables measured 170 throughout each trial were analysed using a three-way (group x trial x time) mixed-171 design factorial ANOVA. Where a main effect or interaction occurred, Bonferroni 172 adjusted paired t-tests for normally distributed data or Wilcoxon Signed Rank tests 173 for non-normally distributed data were used. Between-group comparisons during the 174 testpla, precaf and postcaf trials were determined with t-tests for independent 175 samples. In addition to null-hypothesis testing, magnitude-based inferences were 176 made to examine whether the observed differences in total external work produced 177 were meaningful (Hopkins, 2000) . The magnitude of the smallest worthwhile change 178 in performance was set at 3% (~12 kJ), based on the findings of Jenkins et al. (2008) Fig. 2A ). Based on a smallest worthwhile change in performance 207 of 12 kJ, these within-group increases represent an 'almost certainly beneficial' 208 (caffeine group) and 'probably beneficial' (placebo group) effect on performance, 209 respectively (Table. 1) . 210
Chronic caffeine supplementation resulted in a 7.3 ± 6.3% decrease in total external 211 work produced during the postcaf trial compared with precaf (358 ± 89 kJ vs. 383.3 ± 212 75 kJ; ES=-0.31; P=0.025; Fig. 2A ). This diminished response represents a 'probably 213 harmful' effect on performance ( This study examined whether four weeks of controlled caffeine intake influenced 276 endurance performance in a group of recreationally active men with low-habitual 277 caffeine intakes. The results of the present study indicate that chronic 278 supplementation with a titrated low dose of caffeine developed tolerance to the 279 ergogenic effect a subsequent acute caffeine dose. While these results contrast with 280 previous studies that have examined effects of sub-chronic caffeine supplementation 281 (Irwin et al., 2011) , this is the first study to examine effects of a prolonged period of 282 controlled caffeine intake typical of the general population (Fitt et al., 2013) . This 283 suggests that supplementation protocols in previous studies (Irwin et al., 2011) were 284 too short to influence mechanisms that develop tolerance. 285 enhanced fat oxidation late in exercise with a subsequent sparring of muscle 287 glycogen (Costill, Dalsky, & Fink, 1978) . The results of the present study are contrary 288 to this as substrate oxidation was not influenced either by acute or chronic caffeine 289 supplementation. Alternatively, chronic caffeine intake could influence caffeine 290 metabolism (Svenningsson et al., 1999) . This might lead to an increase in the 291 concentrations of paraxanthine and theophylline, caffeine's primary metabolites 292 (Svenningsson et al., 1999) . As these possess a greater affinity for adenosine 293 receptors than caffeine (Fredholm et al., 1999) , this could result in enhanced 294 development of tolerance. However, caffeine concentrations were similar between 295 the precaf and postcaf trials in the caffeine group (Table. 2), suggesting the 296 habituation protocol failed to influence caffeine metabolism. Although paraxanthine 297 and theophylline concentrations were not measured, these methylxanthines do not 298 penetrate the blood-brain-barrier with the same efficacy as caffeine (Svenningsson 299 et al., 1999) . Therefore, any subtle change in the peripheral concentrations of these 300 metabolites attributable to the chronic supplementation protocol is unlikely to explain 301 the development of tolerance. (Table. 2). Based on these observations, it could be that 328 the 3 mg·kg −1 caffeine dose administered in the present study resulted in the 329 occupation of approximately a quarter of cerebral A 1 receptors. This suggests 330 supplementation with larger daily caffeine doses (i.e. 6-9 mg·kg −1 ), which will 331 ultimately occupy more A 1 receptors, results in accelerated and/or total development 332 of tolerance. 333
The influence of caffeine habituation in participants is often overlooked in many 334 studies, despite evidence which demonstrates that this influences effects after acute 335 supplementation (Bell & McLellan, 2002) . To minimise this confounder, all 336 participants in the present study were low caffeine consumers before participation. & Covert, 2015) . Perhaps this could explain the small between-group 345 difference in total external work produced during the precaf trial (28.7 ± 74.8 kJ; 346 ES=0.44), with more TT carriers present in the caffeine group. However, genotype 347 determination was not undertaken in the present study, which limits the extent to 348 which this relationship can be inferred. 349
Well-trained individuals produce more reliable performance data during cycle-based 350 time-trials than their recreationally active counterparts (Zavorsky et al., 2007) . 351
However, recreationally active individuals produced a CV of 1.7% (Zavorsky et al., 352 2007) and 0.7% (Fleming and James, 2014) during cycle and running-based time-353 trials, respectively. Furthermore, similar performance tests to that in the present 354 study had a CV of approximately 3% (Jeukendrup et al., 1996) . This variability is less 355 than the percentage increase in performance during the precaf trials (caffeine: 12.0 ± 356 7.4%; placebo: 6.7 ± 4.2%) and the percentage decrease in performance during the 357 postcaf trial compared with precaf in the caffeine group (-7.3 ± 6.3%). Therefore, 358 neither the participant group nor the performance test used in the present study 359 adversely influenced the validity of the performance data.
Ideally, the study design would have incorporated a post-supplementation placebo 361 trial, hence providing a direct comparison with the postcaf trial after the chronic 362 supplementation protocol. It was deemed difficult to implement as timing both trials 363 to occur at the end of the supplementation period was not possible. For example, 364 two randomised trials, undertaken seven days apart, means the supplementation 365 period before the postcaf trial would be twenty-eight days for half the participants 366 and thirty-five days for the remaining participants. Importantly, peak power output 367 and maximal oxygen uptake were similar between the two V O 2peak tests. Furthermore, 368 heart rate and oxygen uptake during the fixed-intensity exercise was similar during 369 all three trials. This suggests participants maintained similar fitness throughout the 370 study period and exercise intensity was matched before the performance task during 371 each of the experimental trials. Hence, any influence on performance during the 372 postcaf trial in either supplementation group is likely due to participants receiving 373 caffeine or placebo during the chronic supplementation period. 374
In conclusion, the present findings demonstrate that chronic ingestion of a titrated 375 low dose of caffeine results in the development of tolerance in a group of healthy, 376 recreationally active males with low-habitual caffeine intakes. This occurred despite 377 no changes before and after supplementation in circulating caffeine, hormonal 378 concentrations or substrate oxidation. The influence of chronic caffeine intake should 379 be examined in well-trained individuals with low-habitual caffeine intakes. In addition, 380 futures studies should identify when the tolerance to caffeine occurs and examine 381 whether supplementation with larger daily doses (i.e. 6-9 mg·kg −1 ) influences the 382 rate and extent of the development of tolerance. Values are mean ± SD. PLA, Placebo group; CAF, Caffeine group. *denotes a within-trial significant difference (P<0.05) compared with -60. # denotes a significant difference (P<0.05) compared with the corresponding time point in the testpla trial. There were no significant trial x group (P>0.552), time x group (P>0.443) or trial x time x group (P>0.512) interactions for any variable. 
